Immunotherapy for prostate cancer

Robert Jeffrey Karnes, Christopher M. Whelan, Eugene D Kwon

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

The absence of curative therapies for advanced or recurrent forms of prostate cancer has prompted a vigorous search for novel treatment strategies. Immunotherapy encompasses one particularly promising systemic approach to treat prostate cancer. Immune-based strategies to treat prostate cancer have recently been facilitated by the identification of a number of prostate tissue/tumor antigens that can be targeted, either by antibody or T cells, to promote prostate tumor cell injury or death. These same prostate antigens can also be used for the construction of vaccines to induce prostate-specific T cell-mediated immunity. Greater insight into specific mechanisms that govern antigen-specific T cell activation has brought with it a number of innovative methods to induce and enhance T cell-mediated responses against prostate tumors. For instance, autologous dendritic cells loaded with prostate antigens have proved useful to induce prostate-specific T cell activation. Similarly, in vivo manipulations of the T cell costimulatory pathway receptors can greatly facilitate tumorspecific T cell activation and potentiate T cell-mediated responses against a number of malignancies, including prostate cancer. Therefore, in this review we summarize recent advances pertaining to immunotherapeutic approaches to treat prostate cancer.

Original languageEnglish (US)
Pages (from-to)807-817
Number of pages11
JournalCurrent Pharmaceutical Design
Volume12
Issue number7
DOIs
StatePublished - Mar 2006

Fingerprint

Immunotherapy
Prostate
Prostatic Neoplasms
T-Lymphocytes
Costimulatory and Inhibitory T-Cell Receptors
CD27 Antigens
Antigens
Neoplasms
Neoplasm Antigens
Cellular Immunity
Dendritic Cells
Vaccines
Antibodies
Wounds and Injuries
Therapeutics

Keywords

  • Antigen-presenting cells (APCs)
  • Herceptin
  • Interleukin
  • Monoclonal Antibodies
  • Prostate specific membrane antigen (PSMA)

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Immunotherapy for prostate cancer. / Karnes, Robert Jeffrey; Whelan, Christopher M.; Kwon, Eugene D.

In: Current Pharmaceutical Design, Vol. 12, No. 7, 03.2006, p. 807-817.

Research output: Contribution to journalArticle

Karnes, Robert Jeffrey ; Whelan, Christopher M. ; Kwon, Eugene D. / Immunotherapy for prostate cancer. In: Current Pharmaceutical Design. 2006 ; Vol. 12, No. 7. pp. 807-817.
@article{8c7d79717cbb4957baecbe5f3e5e7d28,
title = "Immunotherapy for prostate cancer",
abstract = "The absence of curative therapies for advanced or recurrent forms of prostate cancer has prompted a vigorous search for novel treatment strategies. Immunotherapy encompasses one particularly promising systemic approach to treat prostate cancer. Immune-based strategies to treat prostate cancer have recently been facilitated by the identification of a number of prostate tissue/tumor antigens that can be targeted, either by antibody or T cells, to promote prostate tumor cell injury or death. These same prostate antigens can also be used for the construction of vaccines to induce prostate-specific T cell-mediated immunity. Greater insight into specific mechanisms that govern antigen-specific T cell activation has brought with it a number of innovative methods to induce and enhance T cell-mediated responses against prostate tumors. For instance, autologous dendritic cells loaded with prostate antigens have proved useful to induce prostate-specific T cell activation. Similarly, in vivo manipulations of the T cell costimulatory pathway receptors can greatly facilitate tumorspecific T cell activation and potentiate T cell-mediated responses against a number of malignancies, including prostate cancer. Therefore, in this review we summarize recent advances pertaining to immunotherapeutic approaches to treat prostate cancer.",
keywords = "Antigen-presenting cells (APCs), Herceptin, Interleukin, Monoclonal Antibodies, Prostate specific membrane antigen (PSMA)",
author = "Karnes, {Robert Jeffrey} and Whelan, {Christopher M.} and Kwon, {Eugene D}",
year = "2006",
month = "3",
doi = "10.2174/138161206776056001",
language = "English (US)",
volume = "12",
pages = "807--817",
journal = "Current Pharmaceutical Design",
issn = "1381-6128",
publisher = "Bentham Science Publishers B.V.",
number = "7",

}

TY - JOUR

T1 - Immunotherapy for prostate cancer

AU - Karnes, Robert Jeffrey

AU - Whelan, Christopher M.

AU - Kwon, Eugene D

PY - 2006/3

Y1 - 2006/3

N2 - The absence of curative therapies for advanced or recurrent forms of prostate cancer has prompted a vigorous search for novel treatment strategies. Immunotherapy encompasses one particularly promising systemic approach to treat prostate cancer. Immune-based strategies to treat prostate cancer have recently been facilitated by the identification of a number of prostate tissue/tumor antigens that can be targeted, either by antibody or T cells, to promote prostate tumor cell injury or death. These same prostate antigens can also be used for the construction of vaccines to induce prostate-specific T cell-mediated immunity. Greater insight into specific mechanisms that govern antigen-specific T cell activation has brought with it a number of innovative methods to induce and enhance T cell-mediated responses against prostate tumors. For instance, autologous dendritic cells loaded with prostate antigens have proved useful to induce prostate-specific T cell activation. Similarly, in vivo manipulations of the T cell costimulatory pathway receptors can greatly facilitate tumorspecific T cell activation and potentiate T cell-mediated responses against a number of malignancies, including prostate cancer. Therefore, in this review we summarize recent advances pertaining to immunotherapeutic approaches to treat prostate cancer.

AB - The absence of curative therapies for advanced or recurrent forms of prostate cancer has prompted a vigorous search for novel treatment strategies. Immunotherapy encompasses one particularly promising systemic approach to treat prostate cancer. Immune-based strategies to treat prostate cancer have recently been facilitated by the identification of a number of prostate tissue/tumor antigens that can be targeted, either by antibody or T cells, to promote prostate tumor cell injury or death. These same prostate antigens can also be used for the construction of vaccines to induce prostate-specific T cell-mediated immunity. Greater insight into specific mechanisms that govern antigen-specific T cell activation has brought with it a number of innovative methods to induce and enhance T cell-mediated responses against prostate tumors. For instance, autologous dendritic cells loaded with prostate antigens have proved useful to induce prostate-specific T cell activation. Similarly, in vivo manipulations of the T cell costimulatory pathway receptors can greatly facilitate tumorspecific T cell activation and potentiate T cell-mediated responses against a number of malignancies, including prostate cancer. Therefore, in this review we summarize recent advances pertaining to immunotherapeutic approaches to treat prostate cancer.

KW - Antigen-presenting cells (APCs)

KW - Herceptin

KW - Interleukin

KW - Monoclonal Antibodies

KW - Prostate specific membrane antigen (PSMA)

UR - http://www.scopus.com/inward/record.url?scp=33645314115&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645314115&partnerID=8YFLogxK

U2 - 10.2174/138161206776056001

DO - 10.2174/138161206776056001

M3 - Article

C2 - 16515497

AN - SCOPUS:33645314115

VL - 12

SP - 807

EP - 817

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

SN - 1381-6128

IS - 7

ER -